Fulcrum Therapeutics (NASDAQ:FULC) Price Target Increased to

Fulcrum Therapeutics (NASDAQ:FULC – Free Report) had its price objective upped by Piper Sandler from $13.00 to $15.00 in a research note published on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock. Separately, The Goldman Sachs Group lifted their price target on shares of Fulcrum Therapeutics from $5.00 to […]

Related Keywords

United States , Piper Sandler , Citigroup Inc , Fulcrum Therapeutics Company Profile , Tower Research Capital , Goldman Sachs Group , Fulcrum Therapeutics Inc , Proshare Advisors , Fulcrum Therapeutics , Free Report , Moderate Buy , Share Advisors , Research Capital , Get Free Report , Fulcrum Therapeutics Daily , Nasdaq Fulc , Fulc , Medical , Boost Price Target ,